ING GROEP NV SCHEDULE 13G/A filed 2026-09-11

ING GROEP NV filed a SCHEDULE 13G/A with the SEC on 2026-09-11 under accession number 0001140361-26-036327. The available text is Exhibit A, a Joint Filing Agreement made pursuant to Rule 13d-1(k). In it, the Reporting Persons agree that a joint statement on this Schedule 13G be filed on their behalf by ING Groep N.V. Each Reporting Person is responsible for the completeness and accuracy of the information about itself, but not for the information about any other Reporting Person. The agreement is dated September 11, 2026. Bianca Jennifer Dobrescu and Ioana Adriana Barbu signed for ING GROEP N.V., both as Authorized Representative. Anthony Masciangelo, Director, and Tim Casady, Authorized Person, signed for ING CAPITAL MARKETS LLC. For a reader tracking who reports positions, this shows that the parent entity and ING CAPITAL MARKETS LLC are reporting together, with ING Groep N.V. as the filer. EDGAR Radar links this filing to two entities. The first is ING GROEP NV, CIK 1039765, classified under SIC 6029, Commercial Banks, NEC. It trades as ING and INGVF on NYSE and OTC, is a Large accelerated filer, and has a business address of PO BOX 1800, AMSTERDAM, Netherlands, 1000 BV. The second is TENAX THERAPEUTICS, INC., CIK 34956, classified under Pharmaceutical Preparations and listed as TENX on Nasdaq, with an address in CHAPEL HILL, NC. The excerpt itself does not name Tenax Therapeutics or any other issuer. The issuer whose securities are reported, the class of securities, the number of shares held, the percentage of the class, and what changed from the earlier statement are not in the filing as excerpted here. Readers can find the full document at the source_url.